ArticleFrontiers in medicine2026
From skin aging biomarkers to precision esthetic longevity: a translational diagnostic framework.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Skin aging is commonly evaluated through visible phenotype, clinical grading, and photographic documentation, yet these approaches incompletely capture the biological mechanisms that shape tissue quality, regenerative capacity, and long-term response to intervention. Recent advances in longevity science, including skin-specific epigenetic clocks, molecular profiling, functional tissue assessment, imaging technologies, and artificial intelligence-derived digital phenotyping create an opportunity to redefine esthetic dermatology as a more biologically informed and longitudinally guided discipline. This article combines a critical synthesis of the current literature with an original translational diagnostic framework for precision esthetic longevity, integrating five complementary layers: systemic biological age and longevity biomarkers; skin- and tissue-specific molecular biomarkers, including epigenetic, senescence-related, inflammatory, glycation, oxidative damage, extracellular matrix, and barrier-related domains; functional biomarkers reflecting elasticity, hydration, microcirculation, barrier integrity, and healing capacity; imaging-based and morphometric diagnostics capturing structural, optical, and spatial features of skin and facial aging; and digital phenotyping tools that may support standardized assessment and longitudinal monitoring. The central premise is that esthetic aging should not be interpreted as a single surface phenotype, but as the visible and measurable expression of interacting systemic, molecular, functional, structural, and digital dimensions. Biological age biomarkers and epigenetic clocks may provide systemic context, whereas skin-specific molecular and imaging biomarkers may offer more direct insight into local tissue aging. However, most available tools remain insufficiently validated for esthetic treatment selection or claims of biological rejuvenation. We therefore emphasize analytical validity, clinical validity, reproducibility, standardization, phototype-inclusive validation, and clinically meaningful endpoints as prerequisites for responsible translation. To make this actionable, we outline a methodological road map for prospectively validating the framework in future multilayer biomarker studies. A layered diagnostic model may support the transition from appearance-based assessment toward mechanism-informed esthetic medicine while maintaining caution regarding overinterpretation, commercialization, and premature clinical adoption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.